The three countries within the East African leDEA Regional Consortium (Kenya, Uganda, Tanzania) have adult HIV prevalence rates ranging between 5-10%.Since the advent of the global antiretroviral therapy (ART) rollout in 2003, there has been a dramatic increase in the percent coverage of those estimated in need of ART (based on the 2006 WHO guidelines), from essentially no patients on in 2003, to 65% coverage in Kenya, 53% in Uganda, and 44% in Tanzania by the end of 2009. Though this dramatic scale-up of HIV treatment has had a positive impact on mortality rates, key questions remain throughout the course of a patient's engagement in care, from the pre- ART period through ART-initiation, initial clinical response to ART and regimen durability (occurrence of adverse events and drug resistance), to long-term maintenance, loss to follow-up (LTFU), and death. It is the long-range goal of this consortium is to provide answers to the questions that clinicians, programs, and ministries of health consider fundamental to the evolution and sustainability of their long term HIV care and treatment strategies. In the next funding cycle, we will address these questions by enhancing data collection in key areas as well as merging existing data sources to better assess and inform the ART rollout in East Africa. We are optimally placed to lead this endeavor as our consortium includes representative HIV-clinics, a harmonized regional database, as well as physicians, epidemiologists, and analysts with expertise in implementation research and a solid understanding of the strengths and limitations of existing data sources. Our top priorities for the next phase of the EA-leDEA Consortium are to:
Aim 1 : Determine the short and long-term outcomes of adults and children along the entire spectrum of HIV care and examine patient and site-level factors associated with these outcomes;
Aim 2 : Assess the penetrance and outcomes of prevention of mother to child transmission of HIV (pMTCT) strategies;
Aim 3 : Monitor the translation of evidence into practice for managing co-infections with an emphasis on Tuberculosis (TB);
Aim 4 : Determine the prevalence, incidence, determinants and outcomes of malignancies in East Africa with a focus on Kaposi's sarcoma (KS) and cervical cancer.

Public Health Relevance

Through these efforts, we will enhance our understanding about the HIV-epidemic in its sub- Saharan Africa context, provide insights on the optimal structure and impact of care and treatment programs, expand the set of tools available to inform implementation and operations research in resource-constrained settings and inform policy among stakeholders and decision makers at every level in the region as well as the broader HIV/AIDS scientific community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069911-08
Application #
8513230
Study Section
Special Emphasis Panel (ZAI1-BB-A (M2))
Program Officer
Zimand, Lori B
Project Start
2006-08-05
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
8
Fiscal Year
2013
Total Cost
$2,025,270
Indirect Cost
$436,215
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Olney, Jack J; Braitstein, Paula; Eaton, Jeffrey W et al. (2016) Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study. Lancet HIV 3:e592-e600
Amerson, Erin; Woodruff, Carina Martin; Forrestel, Amy et al. (2016) Accuracy of Clinical Suspicion and Pathologic Diagnosis of Kaposi Sarcoma in East Africa. J Acquir Immune Defic Syndr 71:295-301
Camlin, Carol S; Neilands, Torsten B; Odeny, Thomas A et al. (2016) Patient-reported factors associated with reengagement among HIV-infected patients disengaged from care in East Africa. AIDS 30:495-502
Charles, M Katherine; Lindegren, Mary Lou; Wester, C William et al. (2016) Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control (""Three I's"") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One 11:e0153243
Saito, Suzue; Mpofu, Philani; Carter, E Jane et al. (2016) Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012. J Acquir Immune Defic Syndr 71:e96-e106
Rebora, Paola; Antolini, Laura; Glidden, David V et al. (2016) Crude incidence in two-phase designs in the presence of competing risks. BMC Med Res Methodol 16:5
Rachlis, Beth; Karwa, Rakhi; Chema, Celia et al. (2016) Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. Drug Saf 39:959-76
Coleman, Jenell S; Cespedes, Michelle S; Cu-Uvin, Susan et al. (2016) An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa. J Low Genit Tract Dis 20:31-7
Gourlay, Annabelle; Wringe, Alison; Todd, Jim et al. (2016) Uptake of services for prevention of mother-to-child transmission of HIV in a community cohort in rural Tanzania from 2005 to 2012. BMC Health Serv Res 16:4
Elul, Batya; Wools-Kaloustian, Kara K; Wu, Yingfeng et al. (2016) Untangling the Relationship Between Antiretroviral Therapy Use and Incident Pregnancy: A Marginal Structural Model Analysis Using Data From 47,313 HIV-Positive Women in East Africa. J Acquir Immune Defic Syndr 72:324-32

Showing the most recent 10 out of 70 publications